Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: A randomized trial

Annals of Internal Medicine

Volumn 153, Issue 1, 2010, Pages 8-18

  Hull, Russell D ^a   Schellong, Sebastian M ^b   Tapson, Victor F ^c   Monreal, Manuel ^d   Samama, Meyer Michel ^e   Nicol, Philippe ^f   Vicaut, Eric ^g   Turpie, Alexander G G ^h   Yusen, Roger D ⁱ  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Départment d'Hématologie Biologique ^*  (Spain)

^e HÔTEL DIEU   (France)

^f SANOFI   (France)

^g HÔPITAL FERNAND WIDAL   (France)

^h HAMILTON GENERAL HOSPITAL   (Canada)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; PLACEBO; ANTICOAGULANT AGENT;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BED REST; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; HOSPITALIZATION; IMMOBILIZATION; INCIDENCE; MIDDLE AGED;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; IMMOBILIZATION; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 77955951754     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-1-201007060-00004     Document Type: Article

References (20)

1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:381S-453S. [PMID: 18574271]
2. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793-800. [PMID: 10477777]
3. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-9. [PMID: 15289368]
4. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325-9. [PMID: 16439370]
5. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol. 1997;50:609-10. [PMID: 9306945]
6. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756-64. [PMID: 17938798]
7. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001;135:858-69. [PMID: 11712876]
8. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a metaanalysis of the randomised trials. Lancet. 2001;358:9-15. [PMID: 11454370]
9. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975-80. [PMID: 11919306]
10. Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, Nielsen JD, Horn A, Mohn AC, et al; FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006;4:2384-90. [PMID: 16881934]
11. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AG, et al. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis. 2006;22:31-8. [PMID: 16786230]
12. Kucher N, Leizorovicz A, Vaitkus PT, Cohen AT, Turpie AG, Olsson CG, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005;165:341-5. [PMID: 15710801]
13. Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med. 2004;164:2260-5. [PMID: 15534164]
14. Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179:417-26. [PMID: 18725614]
15. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006;368:371-8. [PMID: 16876665]
16. Wille-Jørgensen P, Jorgensen LN, Crawford M. Asymptomatic postoperative deep vein thrombosis and the development of postthrombotic syndrome. A systematic review and meta-analysis. Thromb Haemost. 2005;93:236-41. [PMID: 15711738]
17. Lloyd NS, Douketis JD, Moinuddin I, Lim W, Crowther MA. Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. J Thromb Haemost. 2008;6:405-14. [PMID: 18031292]
18. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost. 2005;93:76-9. [PMID: 15630494]
19. Hirsh J, Guyatt G, Lewis SZ. Reflecting on eight editions of the American College of Chest Physicians antithrombotic guidelines [Editorial]. Chest. 2008;133:1293-5. [PMID: 18574282]
20. Hull RD. Thromboprophylaxis in knee arthroscopy patients: revisiting values and preferences [Editorial]. Ann Intern Med. 2008;149:137-9. [PMID: 18626053]